Premium
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength
Author(s) -
Kickler Nils,
Krack Paul,
Fraix Valérie,
Lebas JeanFrançois,
Lamalle Laurent,
Durif Franck,
Krainik Alexandre,
Rémy Chantal,
Segebarth Christoph,
Pollak Pierre
Publication year - 2007
Publication title -
nmr in biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 114
eISSN - 1099-1492
pISSN - 0952-3480
DOI - 10.1002/nbm.1141
Subject(s) - glutamate receptor , basal ganglia , parkinson's disease , creatine , dopamine , medicine , neurotransmitter , neuroscience , endocrinology , psychology , disease , central nervous system , receptor
Abstract Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia. The purpose of this study was to assess these changes in the lentiform nucleus using MRS with optimized glutamate sensitivity ( TE ‐averaged method). Ten patients with Parkinson's disease and 10 healthy controls were examined. Compared with healthy controls, no significant differences in glutamate were measured in patients, but a trend to lower total creatine was observed. Copyright © 2007 John Wiley & Sons, Ltd.